| [1] |
Briganti A,Chun FK,Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer[J]. BJU Int, 2006, 98(4): 788-793.
|
| [2] |
Wilczak W,Wittmer C,Clauditz T, et al. Marked prognostic impact of minimal lymphatic tumor spread in prostate cancer[J]. Eur Urol, 2018, 74(3): 376-386.
|
| [3] |
Sundi D,Tosoian JJ,Nyame YA, et al. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers[M]. Cancer, 2018.
|
| [4] |
Grosu AL,Weirich G,Wendl C, et al. 11C-Choline PET/pathology image coregistration in primary localized prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2014, 41(12): 2242-2248.
|
| [5] |
Abreu A,Fay C,Park D, et al. Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series[J]. BJU Int, 2017, 120(3): 401-408.
|
| [6] |
Winter A,Henke RP,Wawroschek F. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up[J]. BMC Urol. 2015, 15:10.
|
| [7] |
Kaplan AL,Hu JC,Morgentaler A, et al. Testosterone therapy in men with prostate cancer[J]. Eur Urol, 2016, 69(5): 894-903.
|
| [8] |
Maurer T,Robu S,Schottelius M, et al. 99mTechnetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer[J]. Eur Urol. 2018, pii: S0302-2838(18)30189-1.
|
| [9] |
Manny TB,Patel M,Hemal AK. Fluorescence-enhanced robotic radical prostatectomy using real-time lymphangiography and tissue marking with percutaneous injection of unconjugated indocyanine green: the initial clinical experience in 50 patients[J]. Eur Urol, 2014, 65(6): 1162-1168.
|